{"entity":{"id":"nct07617389","kind":"trial","name":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cance","aka":[],"tldr":"A phase 3 trial in lung cancer, run by Wen-zhao ZHONG, not yet recruiting.","summary":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study) is a phase 3, randomised interventional study registered as NCT07617389 by Wen-zhao ZHONG, with a registry enrolment figure of 358 participants, started 2026-05-20 and due to reach its primary completion in 2030-05-15. Interventions recorded: selective mediastinal lymph node sampling; systematic mediastinal lymph node dissection. Conditions listed: Stage IIA-IIIB NSCLC; Selective Mediastinal Lymph Node Sampling; Systematic medIastinal Lymph Node Dissection. Primary outcome: 2-year event-free survival (EFS) rate. Lung eligibility wording from the registry: \"Histologically or pathologically confirmed peripheral non-small cell lung cancer (NSCLC), with clinical tumor, node, metastasis(TNM) stage IIA-IIIB, which according to the International Association for the Study of Lung Cancer(IASLC) 9th edition, and no known epidermal growth factor receptor (EGFR) \". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07617389","url":"https://clinicaltrials.gov/study/NCT07617389"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07617389","phase":"3","setting":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer","sponsor":"Wen-zhao ZHONG","enrolled":358,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07617389/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}